SIRPant Immunotherapeutics

SIRPant Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapies. It is currently in the preliminary development of a novel autologous macrophage therapy for the treatment of aggressive cancers with unmet medical needs. The company believes that its proprietary technology, which can enhance patients' innate and adaptive immune responses to cancer, will play a leading role in the success of next-generation treatments.